ClinicalTrials.gg
CompletedNCT04009382BDJUpdated Nov 6, 2026Results posted

Modulation Effects of Baduanjin Exercise on Subjective Cognitive Decline

An interventional study of Baduanjin Exercise and Cognitive Fitness Program in Cognitive Decline, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

How we know

Updated Nov 6, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital — 14 open to participants now, 16 under way, none of them phase 3. Cognitive Dysfunction · Massachusetts General Hospital.

Enrollment
5th of 27
124 · median 40
Started
2020
with 2 others
No phase
17 of 33
7 open now
Registered
9th of 33
by date

Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2020, is one of 17 with no phase, and was the 9th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

14 of the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The aim of this study is to investigate the modulation effects of Baduanjin (BDJ), a simple and innovative mind-body exercise, on cognitive function, resting state functional connectivity, and brain morphometry in individuals with subjective cognitive decline (SCD). The results obtained will provide novel insights for improving the prevention of age-related cognitive decline and Alzheimer's disease.

Read the detailed description

Subjective cognitive decline (SCD), the self-reported perception of memory or cognitive problems, is receiving increasing attention as a risk factor for the development of Alzheimer's disease (AD). Since SCD manifests before the onset of clinical impairment, it might be the optimal stage/window of time at which to intervene with preventative therapies for AD and age-related dementia before the progressive neurological loss and irreversible cognitive impairment.

Recently, mind-body interventions have demonstrated their potential in preventing cognitive decline. Nevertheless, these mind-body therapies encompass a family of complex practices, each with different characteristics and focus. Therefore, they may be associated with different mechanisms and treatment effects. Baduanjin (BDJ) is an innovative and simple mind-body exercise consisting of eight simple movements that can be easily practiced at home with video guidance, thereby making it a more suitable option for older adults with cognitive decline than other more complex exercises.

We believe that this study will 1) significantly improve the prevention of MCI and AD and directly benefit patients suffering from these highly prevalent disorders, 2) enhance the investigators' understandings of the neurobiology through which mind-body interventions affect cognition and health, and 3) advance the investigators' understandings of the pathophysiology and development of SCD, AD, and age-related dementia.

03

Conditions studied

  • Cognitive Decline
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50 - 80 years old
  • Self-reported experience of persistent decline in memory compared with a previous state (within the past 5 years), which was further confirmed by informants
  • Concerns regarding memory problems
  • , Second Edition (MMSE-2) scores within the normal range
  • Montreal Cognitive Assessment scores within the normal range (adjusted for age, sex, and education)
  • Clinical Dementia Rating score of 0 (no memory loss or slight, inconsistent forgetfulness)

Exclusion criteria

Exclusion Criteria:

  • Unable to speak or read English
  • Diagnosis of depression
  • Other diseases that cause cognitive decline (e.g., traumatic brain injury, stroke, neurodegenerative diseases, brain tumor, Parkinson disease, encephalitis or epilepsy, thyroid dysfunction, severe anemia, syphilis)
  • History of psychosis or congenital mental growth retardation
  • Any delayed recall index greater than 1.5 SD below average on the California Verbal Learning Test, Second Edition
  • Failing the Memory items on the -2 and MDRS-2, as well as the CVLT-II criterion
  • Inability to participate in a 6-month intervention with a 3-month follow-up
  • Any item = 0 on the Lawton-Brody Instrumental Activities of Daily Living Scale for cognitive reasons
  • No available informant
  • Previous diagnosis of MCI, AD, or other age-related dementia
  • Previous Baduanjin experience
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Baduanjin

    This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).

    Other: Baduanjin Exercise

  • Active comparator
    Cognitive Fitness Program

    This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).

    Other: Cognitive Fitness Program

Interventions

  • OtherBaduanjin Exercise

    Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.

  • OtherCognitive Fitness Program

    Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Alzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite

    The ADCS-PACC is a composite of well-validated neuropsychological tests selected for their sensitivity to detect the earliest cognitive decline from normal to subtly abnormal performance. In this study, the ADCS-PACC will be reported as a z-transformed composite score, where a z-score of 0 represents the reference population mean and each 1.0 z-score unit corresponds to one standard deviation (SD) from that mean. Higher (more positive) z-scores indicate better cognitive performance, whereas lower (more negative) z-scores indicate worse cognitive performance. We will interpret changes over time as standardized change in global cognition. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention).

    Time frame: baseline, 3, 6, 9 months

  2. Functional Connectivity of Hippocampus and DLPFC

    Resting-state functional connectivity (rsFC) between the hippocampus and the dorsolateral prefrontal cortex (DLPFC) will be quantified from resting-state functional magnetic resonance imaging (rs-fMRI) data. Specifically, we will compute the correlation between the hippocampal seed time series and the time series from a right DLPFC region of interest (ROI), and report connectivity as a Fisher r-to-z-transformed correlation coefficient (zFC) to support statistical inference. Higher (more positive) zFC values indicate stronger positive coupling, values near 0 indicate little to no coupling, and negative values indicate anticorrelation between regions. In typical rs-fMRI data, Fisher z-transformed connectivity values generally fall within an interpretable range of approximately -0.5 to +0.5. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention) and the prespecified primary endpoint.

    Time frame: baseline, 3, 6 months

Secondary outcomes

  1. The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory Domain

    The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory domain is an 8-item self-report measure of perceived changes in everyday memory functioning compared with the participant's functioning approximately 10 years earlier. Each item is rated on a 4-point scale ranging from 1 (better or no change) to 4 (consistently much worse). The Everyday Memory domain score is calculated as the average of the completed item scores and ranges from 1 to 4. Higher scores indicate greater perceived decline in everyday memory functioning and represent a worse outcome, while lower scores indicate less perceived decline and represent a better outcome. Here we report the change in this score from baseline to the post-treatment assessment (post-treatment (6 month) - baseline).

    Time frame: baseline, 3, 6, 9 months

  2. Patient Reported Outcomes Measurement Information System 29 (PROMIS-29)

    PROMIS-29 domain subscore is used to assess Physical Function (includes 4 items). Physical Function score ranges from 4-20 (higher = better function). We report the change in Physical Function from baseline to 6 months as the pre-specified primary time point.

    Time frame: baseline, 3, 6, 9 months

  3. Brain Morphometry

    We will quantify bilateral hippocampal volume at baseline and Month 6 (end of intervention) and report the change (Month 6 - baseline). Volumes will be reported in mm³ (and, if applicable, normalized to total intracranial volume). Higher volume indicates greater structural integrity; decreases indicate atrophy. Values are non-negative and typically \~2,000-5,000 mm³ per hemisphere in adults (method- and age-dependent). We will report the observed mean change scores (Δmm³).

    Time frame: baseline, 3, 6 months

  4. Blood Markers

    p-tau217 (Tau 217) is a blood/CSF biomarker closely linked to Alzheimer's pathology, rising early with amyloid and increasing further with tau tangle burden. "Normal range" is assay-specific; amyloid-negative values are often \~0.2 pg/mL, with rule-in/abnormal cutoffs commonly \~0.33 pg/mL (plus a gray zone).

    Time frame: baseline, 3, 6, 9 months

  5. Heart Rate Variability

    Secondary autonomic endpoints from a 5-min ECG included RMSSD. We report change from baseline to 6 months (6-month minus baseline) because 6 months was the prespecified primary time point (end of the intervention), intended to capture more sustained effects while reducing short-term variability/attrition. RMSSD (ms) is non-negative (0 to unbounded) and is commonly used as an index of parasympathetic/vagal modulation.

    Time frame: baseline, 3, 6, 9 months

  6. Beck Anxiety Inventory (BAI)

    The Beck Anxiety Inventory (BAI) is a 21-item self-report measure of anxiety symptom severity over the past week. Total scores range from 0 to 63 (higher scores indicate greater anxiety). We evaluated change from baseline to month 6, the end of the intervention.

    Time frame: baseline, 3, 6, 9 months

  7. Symbol Digit Modalities Test (SDMT)

    The Symbol Digit Modalities Test (SDMT) is a brief, well-validated measure of processing speed, attention, and visual scanning. Performance is typically the number of correct symbol-digit pairings completed within the time limit (commonly 90 seconds), with scores ranging from 0 to 110 (higher is better). We evaluated change from baseline to month 6, the end of the intervention.

    Time frame: baseline, 3, 6, 9 months

  8. The Stroop Color and Word Test (SCWT)

    The Stroop Color and Word Test (SCWT) is a widely used measure of selective attention, processing speed, and inhibitory control. Specifically, it measures the ability to suppress the automatic tendency to read a word rather than name the ink color. The slowing in performance caused by this conflict is called Stroop interference. The interference score is often calculated as the additional time required to complete the incongruent color-word condition relative to a baseline (neutral or congruent) condition, with lower time indicating better performance. Scores range from approximately 0 seconds (no interference) to an unbounded upper limit constrained by test duration. We report the change in interference score from post-treatment to baseline.

    Time frame: baseline, 3, 6, 9 months

  9. Trail Making Test Parts A and B Set-Shifting Cost

    The Trail Making Test (TMT) Parts A and B measure processing speed, attention, and executive function. Part A assesses visual scanning and speeded sequencing, while Part B additionally requires set-shifting between numbers and letters. Performance on each part is measured as completion time in seconds, with shorter completion times indicating better performance. The outcome reported is the set-shifting cost, calculated as (TMT Part B completion time - TMT Part A completion time)/(TMT Part B completion time + TMT Part A completion time). This is intended to quantify the additional time required for the executive set-shifting demands of Part B while accounting for individual differences in overall processing speed. Lower values indicate better executive performance, whereas higher values indicate worse executive performance. The measure has no established clinical cutoff or threshold values. We report the change in set-shifting cost from baseline to post-treatment.

    Time frame: baseline, 3, 6, 9 months

  10. Controlled Oral Word Association Test, Category Fluency and Category Switching

    The Controlled Oral Word Association Test (COWAT), Category Fluency, and Category Switching assess verbal fluency and executive control (letter-based word generation, semantic word generation, and switching between categories). Participants are asked to alternately generate words belonging to two semantic categories during a timed trial. Scores are typically the number of correct, non-repeated words produced within the timed trial(s) (practical range 0 to \>40, with higher scores indicating better performance). There are no established clinical threshold or cutoff values for this measure. We evaluated change from baseline to month 6.

    Time frame: baseline, 3, 6, 9 months

  11. Patient Reported Outcomes Measurement Information System - Cognition Function and Ability Subset

    The PROMIS® Cognitive Function and Cognitive Function-Abilities item banks assess patient-reported cognitive concerns and perceived cognitive abilities (e.g., memory, attention, mental clarity). Scores are typically reported as T-scores standardized to the U.S. general population (mean 50, SD 10), with higher scores indicating better perceived cognitive function/abilities. We evaluated change from baseline to month 6, the end of the intervention.

    Time frame: baseline, 3, 6, 9 months

  12. The California Verbal Learning Test-II (CVLT-II)

    The California Verbal Learning Test-II (CVLT-II) is a standardized measure of verbal learning and episodic memory for adolescents and adults. The Short-Delay Free Recall trial assesses the ability to recall a word list approximately 2 minutes after completion of the learning phase. Results are reported as age-adjusted Z-scores based on published normative data. A Z-score of 0 represents the normative population mean, positive Z-scores indicate performance above the population mean (better memory performance), and negative Z-scores indicate performance below the population mean (worse memory performance). There are no universally accepted clinical cutoff values for this outcome. We report the change in Short-Delay Free Recall Z-score from baseline to month 6 (end of the intervention).

    Time frame: baseline

  13. Modified Brief Pain Inventory (BPI)

    The Brief Pain Inventory (BPI) is a 15-item questionnaire that assesses pain location, intensity, relief, quality, and pain-related interference with daily functioning and quality of life. Here, we report average pain over the past week on a 0-10 numeric rating scale. Lower scores indicate less pain (better outcome) and higher scores indicate more pain (worse outcome). We analyzed change from baseline to month 6, which is the end of the study, and included only participants reporting pain (i.e., BPI average pain ≥ 1).

    Time frame: baseline, 3, 6, 9 months

  14. Brief Quantitative Sensory Testing (QST)

    Quantitative sensory testing (QST) will be assessed from baseline to month 6, which represents the end of the intervention. QST will include mechanical and heat pain measures, specifically pain threshold and pain tolerance. Expected values can vary by test location/body site (e.g., face vs forearm), as well as participant and contextual factors such as age, sex, skin characteristics, and testing conditions.

    Time frame: baseline, 3, 6, 9 months

07

Results

Posted Nov 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneBaduanjinCognitive Fitness Program
Started6262
Completed4749
Not completed1513

Outcome measures

PrimaryAlzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite

The ADCS-PACC is a composite of well-validated neuropsychological tests selected for their sensitivity to detect the earliest cognitive decline from normal to subtly abnormal performance. In this study, the ADCS-PACC will be reported as a z-transformed composite score, where a z-score of 0 represents the reference population mean and each 1.0 z-score unit corresponds to one standard deviation (SD) from that mean. Higher (more positive) z-scores indicate better cognitive performance, whereas lower (more negative) z-scores indicate worse cognitive performance. We will interpret changes over time as standardized change in global cognition. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention).

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · z score
Alzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite
z scoreBaduanjinCognitive Fitness Program
Alzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite0.352323178 ± 0.4678498120.318403324 ± 0.578975626
PrimaryFunctional Connectivity of Hippocampus and DLPFC

Resting-state functional connectivity (rsFC) between the hippocampus and the dorsolateral prefrontal cortex (DLPFC) will be quantified from resting-state functional magnetic resonance imaging (rs-fMRI) data. Specifically, we will compute the correlation between the hippocampal seed time series and the time series from a right DLPFC region of interest (ROI), and report connectivity as a Fisher r-to-z-transformed correlation coefficient (zFC) to support statistical inference. Higher (more positive) zFC values indicate stronger positive coupling, values near 0 indicate little to no coupling, and negative values indicate anticorrelation between regions. In typical rs-fMRI data, Fisher z-transformed connectivity values generally fall within an interpretable range of approximately -0.5 to +0.5. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention) and the prespecified primary endpoint.

Time frame:
baseline, 3, 6 months
Reported as:
Mean · unitless Fisher z value
Functional Connectivity of Hippocampus and DLPFC
unitless Fisher z valueBaduanjinCognitive Fitness Program
Functional Connectivity of Hippocampus and DLPFC0.05 ± 0.1-0.05 ± 0.1
SecondaryThe Everyday Cognition - Participant Report Form (ECog) - Everyday Memory Domain

The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory domain is an 8-item self-report measure of perceived changes in everyday memory functioning compared with the participant's functioning approximately 10 years earlier. Each item is rated on a 4-point scale ranging from 1 (better or no change) to 4 (consistently much worse). The Everyday Memory domain score is calculated as the average of the completed item scores and ranges from 1 to 4. Higher scores indicate greater perceived decline in everyday memory functioning and represent a worse outcome, while lower scores indicate less perceived decline and represent a better outcome. Here we report the change in this score from baseline to the post-treatment assessment (post-treatment (6 month) - baseline).

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · units on a scale
The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory Domain
units on a scaleBaduanjinCognitive Fitness Program
The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory Domain-0.022127329 ± 0.584997441-0.020043732 ± 0.592822098
SecondaryPatient Reported Outcomes Measurement Information System 29 (PROMIS-29)

PROMIS-29 domain subscore is used to assess Physical Function (includes 4 items). Physical Function score ranges from 4-20 (higher = better function). We report the change in Physical Function from baseline to 6 months as the pre-specified primary time point.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · units on a scale
Patient Reported Outcomes Measurement Information System 29 (PROMIS-29)
units on a scaleBaduanjinCognitive Fitness Program
Patient Reported Outcomes Measurement Information System 29 (PROMIS-29)-0.153191489 ± 4.879720727-0.940816327 ± 4.231672166
SecondaryBrain Morphometry

We will quantify bilateral hippocampal volume at baseline and Month 6 (end of intervention) and report the change (Month 6 - baseline). Volumes will be reported in mm³ (and, if applicable, normalized to total intracranial volume). Higher volume indicates greater structural integrity; decreases indicate atrophy. Values are non-negative and typically \~2,000-5,000 mm³ per hemisphere in adults (method- and age-dependent). We will report the observed mean change scores (Δmm³).

Time frame:
baseline, 3, 6 months
Reported as:
Mean · mmΛ3
Brain Morphometry
mmΛ3BaduanjinCognitive Fitness Program
Brain Morphometry-43.2 (-106.2 to 19.79)-27.3 (-89.0 to 34.4)
SecondaryBlood Markers

p-tau217 (Tau 217) is a blood/CSF biomarker closely linked to Alzheimer's pathology, rising early with amyloid and increasing further with tau tangle burden. "Normal range" is assay-specific; amyloid-negative values are often \~0.2 pg/mL, with rule-in/abnormal cutoffs commonly \~0.33 pg/mL (plus a gray zone).

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · pg/ml
Blood Markers
pg/mlBaduanjinCognitive Fitness Program
Blood Markers-0.1 ± 0.3-2.4 ± 9.1
SecondaryHeart Rate Variability

Secondary autonomic endpoints from a 5-min ECG included RMSSD. We report change from baseline to 6 months (6-month minus baseline) because 6 months was the prespecified primary time point (end of the intervention), intended to capture more sustained effects while reducing short-term variability/attrition. RMSSD (ms) is non-negative (0 to unbounded) and is commonly used as an index of parasympathetic/vagal modulation.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · ms
Heart Rate Variability
msBaduanjinCognitive Fitness Program
Heart Rate Variability7.8 ± 27.2-3.5 ± 25.8
SecondaryBeck Anxiety Inventory (BAI)

The Beck Anxiety Inventory (BAI) is a 21-item self-report measure of anxiety symptom severity over the past week. Total scores range from 0 to 63 (higher scores indicate greater anxiety). We evaluated change from baseline to month 6, the end of the intervention.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · units on a scale
Beck Anxiety Inventory (BAI)
units on a scaleBaduanjinCognitive Fitness Program
Beck Anxiety Inventory (BAI)-0.425531915 ± 6.439499983-0.673469388 ± 5.665641164
SecondarySymbol Digit Modalities Test (SDMT)

The Symbol Digit Modalities Test (SDMT) is a brief, well-validated measure of processing speed, attention, and visual scanning. Performance is typically the number of correct symbol-digit pairings completed within the time limit (commonly 90 seconds), with scores ranging from 0 to 110 (higher is better). We evaluated change from baseline to month 6, the end of the intervention.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · score on a scale
Symbol Digit Modalities Test (SDMT)
score on a scaleBaduanjinCognitive Fitness Program
Symbol Digit Modalities Test (SDMT)4.608695652 ± 7.5967193533.416666667 ± 7.359559808
SecondaryThe Stroop Color and Word Test (SCWT)

The Stroop Color and Word Test (SCWT) is a widely used measure of selective attention, processing speed, and inhibitory control. Specifically, it measures the ability to suppress the automatic tendency to read a word rather than name the ink color. The slowing in performance caused by this conflict is called Stroop interference. The interference score is often calculated as the additional time required to complete the incongruent color-word condition relative to a baseline (neutral or congruent) condition, with lower time indicating better performance. Scores range from approximately 0 seconds (no interference) to an unbounded upper limit constrained by test duration. We report the change in interference score from post-treatment to baseline.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · seconds
The Stroop Color and Word Test (SCWT)
secondsBaduanjinCognitive Fitness Program
The Stroop Color and Word Test (SCWT)-3.020212766 ± 8.515443385-4.885208333 ± 9.210775371
SecondaryTrail Making Test Parts A and B Set-Shifting Cost

The Trail Making Test (TMT) Parts A and B measure processing speed, attention, and executive function. Part A assesses visual scanning and speeded sequencing, while Part B additionally requires set-shifting between numbers and letters. Performance on each part is measured as completion time in seconds, with shorter completion times indicating better performance. The outcome reported is the set-shifting cost, calculated as (TMT Part B completion time - TMT Part A completion time)/(TMT Part B completion time + TMT Part A completion time). This is intended to quantify the additional time required for the executive set-shifting demands of Part B while accounting for individual differences in overall processing speed. Lower values indicate better executive performance, whereas higher values indicate worse executive performance. The measure has no established clinical cutoff or threshold values. We report the change in set-shifting cost from baseline to post-treatment.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · score on a scale
Trail Making Test Parts A and B Set-Shifting Cost
score on a scaleBaduanjinCognitive Fitness Program
Trail Making Test Parts A and B Set-Shifting Cost0.018268634 ± 0.143499070.004165094 ± 0.138221143
SecondaryControlled Oral Word Association Test, Category Fluency and Category Switching

The Controlled Oral Word Association Test (COWAT), Category Fluency, and Category Switching assess verbal fluency and executive control (letter-based word generation, semantic word generation, and switching between categories). Participants are asked to alternately generate words belonging to two semantic categories during a timed trial. Scores are typically the number of correct, non-repeated words produced within the timed trial(s) (practical range 0 to \>40, with higher scores indicating better performance). There are no established clinical threshold or cutoff values for this measure. We evaluated change from baseline to month 6.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · score on a scale
Controlled Oral Word Association Test, Category Fluency and Category Switching
score on a scaleBaduanjinCognitive Fitness Program
Controlled Oral Word Association Test, Category Fluency and Category Switching0.434782609 ± 2.30605169-0.306122449 ± 3.52493547
SecondaryPatient Reported Outcomes Measurement Information System - Cognition Function and Ability Subset

The PROMIS® Cognitive Function and Cognitive Function-Abilities item banks assess patient-reported cognitive concerns and perceived cognitive abilities (e.g., memory, attention, mental clarity). Scores are typically reported as T-scores standardized to the U.S. general population (mean 50, SD 10), with higher scores indicating better perceived cognitive function/abilities. We evaluated change from baseline to month 6, the end of the intervention.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · T-score
Patient Reported Outcomes Measurement Information System - Cognition Function and Ability Subset
T-scoreBaduanjinCognitive Fitness Program
Patient Reported Outcomes Measurement Information System - Cognition Function and Ability Subset1.693478261 ± 5.6554949552.267346939 ± 4.706794192
SecondaryThe California Verbal Learning Test-II (CVLT-II)

The California Verbal Learning Test-II (CVLT-II) is a standardized measure of verbal learning and episodic memory for adolescents and adults. The Short-Delay Free Recall trial assesses the ability to recall a word list approximately 2 minutes after completion of the learning phase. Results are reported as age-adjusted Z-scores based on published normative data. A Z-score of 0 represents the normative population mean, positive Z-scores indicate performance above the population mean (better memory performance), and negative Z-scores indicate performance below the population mean (worse memory performance). There are no universally accepted clinical cutoff values for this outcome. We report the change in Short-Delay Free Recall Z-score from baseline to month 6 (end of the intervention).

Time frame:
baseline
Reported as:
Mean · z score
The California Verbal Learning Test-II (CVLT-II)
z scoreBaduanjinCognitive Fitness Program
The California Verbal Learning Test-II (CVLT-II).86 ± .95.83 ± .87
SecondaryModified Brief Pain Inventory (BPI)

The Brief Pain Inventory (BPI) is a 15-item questionnaire that assesses pain location, intensity, relief, quality, and pain-related interference with daily functioning and quality of life. Here, we report average pain over the past week on a 0-10 numeric rating scale. Lower scores indicate less pain (better outcome) and higher scores indicate more pain (worse outcome). We analyzed change from baseline to month 6, which is the end of the study, and included only participants reporting pain (i.e., BPI average pain ≥ 1).

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · scores on a scale
Modified Brief Pain Inventory (BPI)
scores on a scaleBaduanjinCognitive Fitness Program
Modified Brief Pain Inventory (BPI)-0.09 ± 1.44-0.26 ± 1.69
SecondaryBrief Quantitative Sensory Testing (QST)

Quantitative sensory testing (QST) will be assessed from baseline to month 6, which represents the end of the intervention. QST will include mechanical and heat pain measures, specifically pain threshold and pain tolerance. Expected values can vary by test location/body site (e.g., face vs forearm), as well as participant and contextual factors such as age, sex, skin characteristics, and testing conditions.

Time frame:
baseline, 3, 6, 9 months
Reported as:
Mean · kPa
Brief Quantitative Sensory Testing (QST)
kPaBaduanjinCognitive Fitness Program
Brief Quantitative Sensory Testing (QST)2.1 ± 5.6-5.6 ± 4.2

Adverse events

Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baduanjin0/62 (0%)3/62 (4.8%)2/62 (3.2%)
Cognitive Fitness Program0/62 (0%)3/62 (4.8%)1/62 (1.6%)
Most frequent serious events
Most frequent serious events
EventBaduanjinCognitive Fitness Program
Gall bladder surgeryGastrointestinal disorders1/620/62
Broken shoulderMusculoskeletal and connective tissue disorders1/620/62
COVID hospitalizationRespiratory, thoracic and mediastinal disorders0/621/62
Staph infectionInfections and infestations0/621/62
Heart attackCardiac disorders0/621/62
Skin CancerSkin and subcutaneous tissue disorders1/620/62
Most frequent other events
Most frequent other events
EventBaduanjinCognitive Fitness Program
Scoliosis painMusculoskeletal and connective tissue disorders1/620/62
Viral infectionInfections and infestations1/620/62
depression episodePsychiatric disorders0/621/62

Baseline characteristics

individuals with subjective cognitive decline were enrolled in the study.

Age, Continuous
Age, Continuous(year)BaduanjinCognitive Fitness ProgramTotal
Mean62.5 ± 12.563.9 ± 8.063.7 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)BaduanjinCognitive Fitness ProgramTotal
Female423577
Male131831
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BaduanjinCognitive Fitness ProgramTotal
Hispanic or Latino224
Not Hispanic or Latino5350103
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BaduanjinCognitive Fitness ProgramTotal
American Indian or Alaska Native000
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American101
White484896
More than one race101
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)BaduanjinCognitive Fitness ProgramTotal
United States5553108
08

Study locations

1 site
  • Massachusetts General Hospital
    Charlestown, Massachusetts 02129, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Feb 2025, 53 months.

Results were first posted in Nov 2026, 1 year 9 months after primary completion.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 53 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2019
First posted
Jul 5, 2019
StartActual
Aug 31, 2020
Primary completionActual
Feb 6, 2025
CompletionActual
Feb 6, 2025
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 6, 2026
Primary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedFunctional connectivityConnectivity of hippocampusHippocampus and DLPFCTime frame: baseline, 3, 6 months
  • DescriptionAlzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite: how it is measured was reworded
Nov 6, 2026
Documents
Secondary outcomes
6 edited, 1 time frame changed, 8 description edited
What changed in the outcomes
  • EditedThe Everyday Cognition -Subject/Self Participant Report Form (ECog) -self report and informant) Everyday Memory DomainTime frame: baseline, 3, 6, 9 months
  • EditedBrain morphometryMorphometryTime frame: baseline, 3, 6 months
  • EditedBlood markersMarkersTime frame: baseline, 3, 6, 9 months
  • EditedHeart rate variabilityRate VariabilityTime frame: baseline, 3, 6, 9 months
  • EditedTrail-making Making Test Parts A and B Set-Shifting CostTime frame: baseline, 3, 6, 9 months
  • EditedPatient Reported Outcomes Measurement Information System - Cognition Function and ability subsetAbility SubsetTime frame: baseline, 3, 6, 9 months
  • Time frameThe California Verbal Learning Test-II (CVLT-II)baseline, 3, 6, 9 months → baseline
  • DescriptionBeck Anxiety Inventory (BAI): how it is measured was reworded
  • DescriptionBrief Quantitative Sensory Testing (QST): how it is measured was reworded
  • DescriptionControlled Oral Word Association Test, Category Fluency and Category Switching: how it is measured was reworded
  • DescriptionModified Brief Pain Inventory (BPI): how it is measured was reworded
  • DescriptionPatient Reported Outcomes Measurement Information System 29 (PROMIS-29): how it is measured was reworded
  • DescriptionSymbol Digit Modalities Test (SDMT): how it is measured was reworded
  • DescriptionThe California Verbal Learning Test-II (CVLT-II): how it is measured was reworded
  • DescriptionThe Stroop Color and Word Test (SCWT): how it is measured was reworded
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Results posted
    Primary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedFunctional connectivityConnectivity of hippocampusHippocampus and DLPFCTime frame: baseline, 3, 6 months
    • DescriptionAlzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite: how it is measured was reworded
    Secondary outcomes 6 edited, 1 time frame changed, 8 description edited
    What changed in the outcomes
    • EditedThe Everyday Cognition -Subject/Self Participant Report Form (ECog) -self report and informant) Everyday Memory DomainTime frame: baseline, 3, 6, 9 months
    • EditedBrain morphometryMorphometryTime frame: baseline, 3, 6 months
    • EditedBlood markersMarkersTime frame: baseline, 3, 6, 9 months
    • EditedHeart rate variabilityRate VariabilityTime frame: baseline, 3, 6, 9 months
    • EditedTrail-making Making Test Parts A and B Set-Shifting CostTime frame: baseline, 3, 6, 9 months
    • EditedPatient Reported Outcomes Measurement Information System - Cognition Function and ability subsetAbility SubsetTime frame: baseline, 3, 6, 9 months
    • Time frameThe California Verbal Learning Test-II (CVLT-II)baseline, 3, 6, 9 months → baseline
    • DescriptionBeck Anxiety Inventory (BAI): how it is measured was reworded
    • DescriptionBrief Quantitative Sensory Testing (QST): how it is measured was reworded
    • DescriptionControlled Oral Word Association Test, Category Fluency and Category Switching: how it is measured was reworded
    • DescriptionModified Brief Pain Inventory (BPI): how it is measured was reworded
    • DescriptionPatient Reported Outcomes Measurement Information System 29 (PROMIS-29): how it is measured was reworded
    • DescriptionSymbol Digit Modalities Test (SDMT): how it is measured was reworded
    • DescriptionThe California Verbal Learning Test-II (CVLT-II): how it is measured was reworded
    • DescriptionThe Stroop Color and Word Test (SCWT): how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04009382
Responsible party
Jian Kong (Professor, Massachusetts General Hospital) — Principal investigator
First posted
Jul 5, 2019
Start date
Aug 31, 2020
Primary completion
Feb 6, 2025
Completion
Feb 6, 2025
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion